Key Metrics 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Ahlcon Parenterals (India) Ltd (524448)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524448 NSE: Pharmaceuticals & Drugs | Small Cap | Ahlcon Parenteral (I Share Price
BSE Share Price
Not Listed
Not Listed
Ahlcon Parenterals (India) Ltd (524448)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524448 NSE: Pharmaceuticals & Drugs | Small Cap | Ahlcon Parenteral (I Share Price
BSE Share Price
Not Listed
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹371 Cr.
Current Price
₹0
52-Week Low / High
₹515 / 517
TTM EPS
-
TTM Sales
-
Book Value per Share
-
P/E Ratio
Industry PE
55
Price to Book (P/B)
Price to Sales (P/S)
EV/EBITDA
Dividend Yield
NAN%
Profitability Efficiency
Return on Equity (ROE)
%
Return on Capital Employed (ROCE)
%
Return on Assets (ROA)
%
Operating Profit Margin
0%
Net Profit Margin
-%
Gross Profit Margin
0%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
32.77%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
93.26%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
-
Equity
₹7.2 Cr.
Face Value
₹10
All Time Low / High
₹2.00 / 598.00
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation ⓘ
| Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 31.5% | 33.5% | 10.4% | -2.3% | 1.1% | -5% | -6.7% | 4.7% | -8.9% | 2.7% | - |
| Value Creation Index ⓘ | 1.3 | 1.4 | -0.3 | -1.2 | -0.9 | -1.4 | NA | NA | NA | NA | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 108 | 120 | 116 | 119 | 135 | 150 | 156 | 174 | 132 | 176 | 176 |
| Sales YoY Gr. | - | 11.4% | -3.3% | 2.6% | 13.8% | 10.5% | 4% | 12.1% | -24.2% | 32.8% | - |
| Adj EPS ⓘ | 17.7 | 27.1 | 24.6 | -19.2 | -11.8 | -62.6 | -67.1 | -20.8 | -64.6 | -28.1 | -27.5 |
| YoY Gr. | - | 53.3% | -9.2% | -178.1% | NA | NA | NA | NA | NA | NA | - |
| BVPS (₹) ⓘ | 75.1 | 102.1 | 124.8 | 99 | 79.8 | 19.5 | -46.6 | -68.2 | -133.5 | -161 | 119.5 |
| Adj Net Profit ⓘ | 12.7 | 19.5 | 17.7 | -13.8 | -8.5 | -45 | -48.3 | -15 | -46.5 | -20.2 | -20 |
| Cash Flow from Ops. ⓘ | 9.3 | 17.1 | 31.2 | 7.8 | 12.7 | 34.7 | 38.7 | 30.3 | 21.4 | 11.5 | - |
| Debt/CF from Ops. ⓘ | 1.9 | 2.5 | 6.6 | 32.1 | 21.5 | 8.3 | 7.6 | 9.9 | 14.6 | 29.6 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 5.6% | 5.4% | 4.1% | 32.8% | ||||
| Adj EPS ⓘ | -205.3% | NA | NA | NA | ||||
| BVPSⓘ | -208.8% | -215.1% | NA | NA | ||||
| Share Price | - | - | - | - | ||||
Key Financial Parameters ⓘ
| Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 26.2 | 30.4 | 21.7 | -17.2 | -13.1 | -126 | 496.3 | 36.2 | 64.1 | 19.1 | 132.5 |
| Op. Profit Mgn % ⓘ | 22.9 | 28.7 | 23.1 | 12.6 | 19.8 | 12.8 | 7.7 | 18.9 | 3.9 | 15.2 | 25.6 |
| Net Profit Mgn % ⓘ | 11.8 | 16.3 | 15.3 | -11.6 | -6.3 | -30.1 | -31.1 | -8.6 | -35.2 | -11.5 | -11.3 |
| Debt to Equity ⓘ | 0.3 | 0.6 | 2.3 | 3.5 | 4.8 | 20.6 | -8.8 | -6.1 | -3.3 | -2.9 | - |
| Working Cap Days ⓘ | 107 | 122 | 149 | 152 | 140 | 141 | 153 | 137 | 149 | 117 | 90 |
| Cash Conv. Cycle ⓘ | 55 | 67 | 86 | 103 | 101 | 90 | 83 | 76 | 82 | 66 | 19 |
Valuation of Ahlcon Parenteral (I - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
No data found!
No data found!
No data found!
No data found!
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Ahlcon Parenterals (India) Ltd FAQs
The current trading price of Ahlcon Parenteral (I on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Ahlcon Parenteral (I stood at ₹370.8 Cr
The latest P/E ratio of Ahlcon Parenteral (I as of 31-Dec-1969 is 0.00.
The latest P/B ratio of Ahlcon Parenteral (I as of 31-Dec-1969 is 4.31.
The 52-week high of Ahlcon Parenteral (I is ₹517.2 and the 52-week low is ₹514.8.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Ahlcon Parenteral (I is ₹176 ( Cr.) .
Data is not available for this company.
No data found
No data found
About Ahlcon Parenterals (India) Ltd
Ahlcon Parenterals (India), incorporated in 1992, is engaged in manufacturing life saving Intravenous fluids and medical disposals by employing a highly sophisticated production process, the aseptic form-fill-seal technology imported from Switzerland.
Ahlcon has an installed capacity of 30 million bottles per annum for LVP in pack size of 100ml and 500ml. Further, 200ml and 300ml packs are being launched in near future.
The company also has capacity of 60 million vials of eye drops and injections in the fill size of 2ml, 3ml, 5ml & 10ml both in transparent and white opaque packs as SVP.
Within a short span of time since its inception, the company has achieved the quality certification from WHO-GMP International and ISO 9002, a landmark achievement which ensures international quality standards with ultimate objective of getting the MCA approval.
Products
Antimicrobial I V fluids, eye and ear drops, ointments, other products such as respiratory solutions, plasma volume expander and many more.
You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
